Model-informed drug discovery and development approaches to inform clinical trial design and regulatory decisions: A primer for the MENA region
2024

Model-informed drug discovery and development in the MENA region

publication Evidence: moderate

Author Information

Author(s): Alasmari Mohammed S., Albusaysi Salwa, Elhefnawy Marwa, Ali Ali M., Altigani Khalid, Almoslem Mohammed, Alharbi Mohammed, Alghamdi Jahad, Alsultan Abdullah

Hypothesis

How can model-informed drug discovery and development (MID3) approaches enhance clinical trial design and regulatory decisions in the MENA region?

Conclusion

The study emphasizes the need for MENA countries to adopt MID3 approaches to improve drug development efficiency and address regional health challenges.

Supporting Evidence

  • MID3 can significantly enhance the efficiency and success rates of drug development tailored to regional health priorities.
  • Successful case studies of applying MID3 at different phases of drug development and clinical trials were discussed.
  • The study calls for MENA countries to invest in workforce training and align regulatory frameworks to support MID3.

Takeaway

This study shows that using smart models can help make better medicines faster and safer for people in the Middle East and North Africa.

Methodology

The review discusses the applications, challenges, and future prospects of MID3 in drug development, emphasizing the integration of local data and computational techniques.

Limitations

The study does not provide specific quantitative data or case studies from the MENA region.

Digital Object Identifier (DOI)

10.1016/j.jsps.2024.102207

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication